DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis

Stock Information for DURECT Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About DURECT Corporation

DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.